From the Guidelines
Eliquis should be stopped for at least 2 days prior to the day of the biopsy, considering the patient's renal function, to minimize bleeding risk while allowing for the procedure to be performed safely. The decision to stop Eliquis after a stroke to allow a biopsy involves weighing the risk of stroke recurrence against the risk of bleeding complications [ 1 ]. For patients on Eliquis (apixaban), a direct oral anticoagulant, the guidelines suggest stopping the medication 2 days before the biopsy or longer if the patient is taking dabigatran, depending on renal function [ 1 ]. This recommendation is based on the guidelines from the British Society of Gastroenterology, the Royal College of Radiologists, and the Royal College of Pathology, published in the journal Gut in 2020 [ 1 ].
- Key considerations include:
- The type of stroke the patient experienced, as this influences the risk of recurrence and the potential for bleeding complications
- The location and nature of the biopsy, as different procedures carry varying levels of bleeding risk
- The patient's renal function, as impaired kidney function can affect the clearance of Eliquis and thus the timing of its discontinuation
- The need for bridging anticoagulation therapy, such as with low molecular weight heparin, in certain cases to mitigate the risk of thromboembolic events during the period when Eliquis is stopped [ 1 ]. After the biopsy, resuming Eliquis depends on achieving adequate hemostasis and assessing the patient's individual risk factors for both bleeding and stroke recurrence [ 1 ]. Generally, Eliquis can be restarted 24-48 hours post-procedure, provided there are no significant bleeding complications [ 1 ]. Collaboration between the neurologist and the physician performing the biopsy is crucial to determine the optimal timing for stopping and restarting Eliquis, balancing the risks of stroke and bleeding [ 1 ].
From the FDA Drug Label
Apixaban tablets should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding [see Warnings and Precautions (5. 2)] . Apixaban tablets should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled.
Stopping Eliquis (apixaban) after a stroke to allow a biopsy:
- The drug label recommends discontinuing apixaban at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding.
- For procedures with a low risk of bleeding, apixaban should be discontinued at least 24 hours prior.
- It is essential to consider the individual patient's risk of bleeding and the specific procedure to determine the appropriate timing for stopping apixaban 2.
From the Research
Stopping Eliquis after a Stroke for a Biopsy
- The studies provided do not directly address when to stop Eliquis (apixaban) after a stroke to allow for a biopsy 3, 4, 5, 6, 7.
- However, the AREST trial 5 compared early anticoagulation with apixaban in patients with atrial fibrillation who had a stroke or transient ischemic attack (TIA) to warfarin administration at later intervals.
- The trial found that early initiation of anticoagulation after TIA, small-, or medium-sized AIS from AF does not appear to compromise patient safety, but the potential efficacy of early initiation of anticoagulation remains to be determined from larger pivotal trials.
- The decision to stop Eliquis for a biopsy would depend on various factors, including the patient's individual risk of stroke and bleeding, as well as the specific procedure and timing of the biopsy.
- It is essential to consider the patient's overall clinical condition and consult with a healthcare professional to determine the best course of action.